KD 5005
Alternative Names: KD-5005Latest Information Update: 03 Jul 2024
At a glance
- Originator Shanghai Celgen Bio-Pharmaceutical
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Recombinant fusion proteins; Tumour necrosis factors
- Mechanism of Action Immunologic cytotoxicity; Tumour necrosis factor alpha replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Apr 2024 Preclinical trials in Cancer in China (IV) prior to April 2024
- 05 Apr 2024 Pharmacodynamics, adverse events and pharmacokinetics data from a preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024 2024)
- 05 Apr 2024 Shanghai Celgen Bio-Pharmaceutical plans a clinical trial for Cancer